Yingcong Wang

301 YanChang Road
Shanghai, 200072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

PIPKI-PIP2 promotes cell migration by recruiting Smurf1 to the membrane and increasing its activity.

PIPKI-PIP2 promotes cell migration by recruiting Smurf1 to the membrane and increasing its activity.

Journal: Acta biochimica et biophysica Sinica

Published: December 30, 2025

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Journal: Cancer research

Published: June 27, 2025

KDM4B enhances immune surveillance via demethylating cGAS.

KDM4B enhances immune surveillance via demethylating cGAS.

Journal: Cell death & disease

Published: December 30, 2024

Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.

Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.

Journal: Bioorganic & medicinal chemistry letters

Published: October 04, 2023

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.

Journal: Journal of translational medicine

Published: September 21, 2023

Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.

Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.

Journal: Leukemia

Published: January 24, 2023

Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma.

Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma.

Journal: Haematologica

Published: January 20, 2023

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Journal: Journal of biomedical science

Published: December 28, 2021

DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.

DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.

Journal: Neoplasia (New York, N.Y.)

Published: June 14, 2021

Quercetin inhibits the proliferation of multiple myeloma cells by upregulating PTPRR expression.

Quercetin inhibits the proliferation of multiple myeloma cells by upregulating PTPRR expression.

Journal: Acta biochimica et biophysica Sinica

Published: April 10, 2021

Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells.

Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells.

Journal: Acta biochimica et biophysica Sinica

Published: October 12, 2020

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.

Journal: American journal of translational research

Published: April 24, 2020

Showing 1-12 of 26

Last Updated: 09/26/2026